Characterization of monoclonal and patient-derived antiplatelet factor 4 antibodies in platelet factor 4 and platelet factor 4/polyanion chemiluminescence assays
Journal of Thrombosis and Haemostasis · 2026-05 · 24 (5) · 1871-1880
DOI: 10.1016/j.jtha.2026.01.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-05. Verfasst von Venkata A S Dabbiru und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany. Hauptthemen laut MEDLINE: Platelet Factor 4, Antibodies, Monoclonal, Luminescent Measurements, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme, American Society of Hematology, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
BACKGROUND: Heparin-induced thrombocytopenia, vaccine-induced immune thrombocytopenia and thrombosis (VITT), and VITT-like disorders are caused by antiplatelet factor 4 (PF4)/polyanion and/or anti-PF4 immunoglobulin G antibodies. The rapid anti-PF4/polyanion and anti-PF4 chemiluminescence assays differentiate between typical heparin-induced thrombocytopenia (anti-PF4/heparin) and VITT antibodies (anti-PF4). OBJECTIVES: To characterize monoclonal antibodies (mAbs) and recombinant anti-PF4 antibodies in the 2 chemiluminescence assays specific for anti-PF4/polyanion and anti-PF4 antibodies, respectively, and to characterize anti-PF4/polyanion antibodies in patients whose sera tested positive in both assays. METHODS: For anti-PF4/heparin and anti-PF4 antibodies, the chimeric mAbs 5B9, 1C12, and 1E12 were generated using standard technology. Recombinant antibodies from VITT and VITT-like patients were generated based on the amino acid sequences of affinity-purified patient anti-PF4 antibodies. KKO was humanized by cloning its Fab sequences and expressing them as a chimeric recombinant human immunoglobulin G1 antibody. Anti-PF4 antibodies from patient sera testing positive in both chemiluminescence assays were affinity-purified using PF4/polyanion and PF4 beads. RESULTS: In chemiluminescence assays, 5B9, humanized KKO, 1C12, and 1E12 bound to PF4/polyanion complexes but differed largely in their PF4 reactivity. VITT (-like) recombinant antibodies bound only to PF4. Some patients' sera contained antibodies that showed similar reactivity in both assays, regardless of whether purified with PF4/polyanion or PF4 beads, suggesting cross-reactive antibodies, while sera from other patients contained both anti-PF4/heparin and anti-PF4 antibodies. CONCLUSION: The different reactivities of anti-PF4 mAbs/heparin antibodies need to be considered when planning experiments and interpreting results. Patients may have very different antibody reactivities despite giving the same results in the 2 chemiluminescence assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany.
- Werfen, Lliçà d'Amunt, Barcelona, Spain.
- Department of Immunology, College of Medicine and Public Health, Flinders University, South Australia Pathology, Bedford Park, South Australia, Australia.
- Institut national de la santé et de la recherche médicale Unité Mixte de Recherche 1327 ISCHEMIA, Université de Tours, Tours, France; Service d'Hématologie-Hémostase, Centre Hospitalier Universitaire de Tours, Tours, Fr…
- Institut für Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Germany. Electronic address: andreas.greinacher@med.uni-greifswald.de.
Förderung
- Horizon 2020 Framework Programme
- American Society of Hematology
- Deutsche Forschungsgemeinschaft
- Else Kröner-Fresenius-Stiftung
- Flinders Foundation
Zitieren
APA
Dabbiru, V. A. S., Broto, M., Wesche, J., Wang, J. J., Müller, L., Gebicka, P., Rollin, J., Gruel, Y., Palicio, M., Thiele, T., Greinacher, A., & Schönborn, L. (2026). Characterization of monoclonal and patient-derived antiplatelet factor 4 antibodies in platelet factor 4 and platelet factor 4/polyanion chemiluminescence assays. Journal of Thrombosis and Haemostasis, 24(5), 1871-1880. https://doi.org/10.1016/j.jtha.2026.01.016
Vancouver
Dabbiru VAS, Broto M, Wesche J, Wang JJ, Müller L, Gebicka P, et al. Characterization of monoclonal and patient-derived antiplatelet factor 4 antibodies in platelet factor 4 and platelet factor 4/polyanion chemiluminescence assays. Journal of Thrombosis and Haemostasis. 2026;24(5):1871-1880. doi:10.1016/j.jtha.2026.01.016
BibTeX
@article{Dabbiru2026,
author = {Dabbiru, Venkata A S and Broto, Marta and Wesche, Jan and Wang, Jing Jing and Müller, Luisa and Gebicka, Patrycja and Rollin, Jérôme and Gruel, Yves and Palicio, Marta and Thiele, Thomas and Greinacher, Andreas and Schönborn, Linda},
title = {Characterization of monoclonal and patient-derived antiplatelet factor 4 antibodies in platelet factor 4 and platelet factor 4/polyanion chemiluminescence assays},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {5},
pages = {1871--1880},
doi = {10.1016/j.jtha.2026.01.016}
}
EUVIMED